Your search for returned 77 results
Order by Relevance | Date
We suggest

Ipergay PrEP study results published

The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina but the researchers ...

Information level Level 3
02 December 2015
From News

Ipergay PrEP study results published

The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina but the researchers

Information level Level 3
02 December 2015
From News

Canada: PrEP use now could save considerable sums in the future

A Canadian paper that weighs the cost of using pre-exposure prophylaxis (PrEP) to prevent HIV infections against the lifetime total cost of one HIV infection finds that, using figures available for Quebec and Ontario provinces, PrEP would be cost-saving under most scenarios, even if the overall lifetime cost of HIV

Information level Level 3
20 March 2015
From News

Pre-exposure prophylaxis also stops 86% of HIV infections in Ipergay study

A French and Canadian study of pre-exposure prophylaxis (PrEP) presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, found that the HIV infection rate in participants taking an intermittent PrEP regime was 86% lower than in people taking an inactive placebo. Extraordinarily, this is

Information level Level 3
24 February 2015
From News

Ipergay trial: PrEP still protected people who had less sex and used it less often

A substudy of the French Ipergay trial of ‘on-demand’ pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented

Information level Level 3
26 July 2017
From News

Key PrEP studies

A wide range of results have been reported in other PrEP studies, with some finding high effectiveness and some none at all. Click on the table to see a larger version. For more information on these studies, click on the following links: CAPRISA 004 , iPrEx , FEM-PrEP , Partners

10 July 2015

Second European PrEP study closes placebo arm early due to high effectiveness

In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomised phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing . The investigators of the IPERGAY trial, which has six sites in France

Information level Level 3
29 October 2014
From News

Good adherence seen in study of intermittent PrEP

The first results published from the IPERGAY study, a trial of pre-exposure prophylaxis (PrEP) in gay men taking place in France and Quebec, Canada, appear to indicate excellent adherence to a novel ‘pre-and-post’ intermittent PrEP strategy designed to save money and reduce time spent taking PrEP unnecessarily. The results were

Information level Level 3
22 July 2014
From News

Intermittent PrEP may be a robust strategy for anal sex – vaginal much less certain

The pharmacodynamics (drug absorption and elimination rates) of the two drugs that comprise Truvada may favour the efficacy of intermittent pre-exposure prophylaxis (PrEP) more than previously thought, at least when it comes to protection from transmission via anal sex, the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and

Information level Level 3
22 July 2015
From News

France approves PrEP

In a historic move, France has become the first country outside the USA, and the first country with a centrally-organised, reimbursable health system, to approve no-expense pre-exposure prophylaxis (PrEP) for people who need it. The French Minister of Health, Marisol Touraine, announced today that PrEP would be available from mid-December,

Information level Level 3
24 November 2015
From News

How a London clinic reduced new HIV infections by 90% and why more European cities can do the same

Scaling up HIV testing to reduce undiagnosed HIV infection requires a fundamental re-ordering of HIV testing services to make them more attractive to people at risk, and doing so can bring about enormous changes in HIV incidence and treatment uptake, delegates heard on the opening day of the 16th European

Information level Level 3
26 October 2017
From News

Gay men are better at predicting when they won’t have sex than when they will

A study in which a group of HIV-negative gay and bisexual men from New York were asked to predict each day whether they would have sex the following day, and then compared their prediction with what actually happened, found that men generally overestimated the likelihood they would have sex. The

Information level Level 3
12 January 2015
From News

France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic

France is launching a new study which will enrol 3000 new pre-exposure prophylaxis (PrEP) users over the next three years, Jean-Michel Molina told the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris this week. Whereas previous studies, including Molina’s own IPERGAY study, proved the benefit of

Information level Level 3
28 July 2017
From News

Condom use in French PrEP trial: half only used PrEP, a quarter used condoms and PrEP, one in six used neither

An analysis of condom use in the placebo-controlled phase of the French IPERGAY trial of intermittent pre-exposure prophylaxis (PrEP), presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) , found that just over half of the participants had high levels of PrEP use but rarely used condoms, and

Information level Level 3
26 February 2016
From News

PrEP rollout recipients in France top 1000: full trial results report 97% effectiveness

Up to July 2016, 1077 people, 96.4% of them gay men, have started HIV pre-exposure prophylaxis (PrEP) through the public healthcare system in France, Jean-Michel Molina, principal investigator of the Ipergay trial, told delegates at the 21st International AIDS Conference (AIDS 2016) . Ninety clinics now offer PrEP assessment and

Information level Level 3
29 July 2016
From News

Cost is biggest barrier to PrEP in Europe, ECDC report declares

A meeting a month ago at the European Centre for Disease Control (ECDC) in Stockholm found that cost was regarded as the biggest barrier to the adoption of HIV pre-exposure prophylaxis (PrEP) by European countries. Many regarded significant price reductions in the drugs used as a pre-condition for adopting PrEP.

Information level Level 3
03 June 2016
From News

PrEP preferences in gay men are predicted by the frequency and predictability of the sex they have

A recently-published survey from the US and Canada reveals that on the whole HIV-negative gay men would rather take pre-exposure prophylaxis (PrEP) intermittently and only before they anticipate sex, in what has been called “event-driven” or “on-demand” PrEP. The study was conducted in 2011 after the iPrEx study results came

Information level Level 3
02 October 2015
From News

Second UK cost-effectiveness study finds that large PrEP programmes may need drug price cut to be affordable

A second UK cost-effectiveness study of pre-exposure prophylaxis (PrEP) has concluded that a medium-sized PrEP rollout programme that started in 2016 and which immediately offered tenofovir/emtricitabine ( Truvada ) as daily PrEP to 5,000 gay men at risk of HIV infection, would not be cost-effective unless the price of Truvada

Information level Level 3
25 September 2015
From News

Sheena McCormack presenting the PROUD study results at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com. A major scientific conference has heard important news about pre-exposure prophylaxis (PrEP), the use by HIV-negative people of antiretrovirals to prevent HIV infection. Two studies of PrEP in gay men and trans women have demonstrated

15 February 2014
From News

NHS urgently needs to make PrEP available, say HIV prevention organisations

A group of community organisations working on HIV prevention have called for the NHS to speed up its processes and make pre-exposure prophylaxis (PrEP) available to those at the highest risk of acquiring HIV. The organisations point to the continued high rate of new infections and say there is an

Information level Level 3
25 November 2014
From News

Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men (MSM) taking part in the Ipergay HIV pre-exposure prophylaxis (PrEP) trial produced a 70% drop in chlamydia infections and a 73% drop in syphilis, but no reduction in gonorrhoea. The results were presented at

Information level Level 3
15 February 2017
From News

Wednesday 25th February 2015

Sheena McCormack presenting the PROUD study results at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com. The most exciting news from CROI concerns pre-exposure prophylaxis (PrEP), the use by HIV-negative people of antiretrovirals to prevent HIV infection. Two studies of PrEP in gay men and trans women have demonstrated that the

25 February 2015
From News

How adherent do people need to be for PrEP to be effective?

By testing participants’ blood for the presence of PrEP drugs, researchers have attempted to estimate the number of PrEP doses they have actually taken. They have then looked at the number of HIV infections in people with different levels of adherence. For example, in the iPrEX OLE study of men

10 July 2015

At least 25,000 people in the US may now be using PrEP

As many as 30,000 people in the US may now be taking pre-exposure prophylaxis to prevent HIV, the fourth IAPAC Controlling the HIV Epidemic with Antiretrovirals summit in Paris heard last week. Meanwhile, as the summit also heard, European and other countries face frustrating delays in securing access. Dr Bob

Information level Level 3
14 October 2015
From News

Daily PrEP leads to better adherence and protective drug levels in women

HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice weekly or before and after sex, according to findings from the HPTN 067 trial presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Information level Level 3
22 April 2015
From News

Wednesday 22 July 2015

Image from presentation by Jacob Levi, Imperial College London, at IAS 2015. Global analysis of HIV treatment cascades – the proportions of people diagnosed with HIV, in care, on treatment and virally suppressed – shows that some of the world’s richest countries are still far short of achieving the UNAIDS

04 March 2015
From News
← First123...4Next →

Filter by date

From
To

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.